In both his practice and his personal life, John P. Berdahl, MD, believes the equipment he uses plays a major role in his outcomes. And with hobbies like scuba diving and hunting, he understands the value of a lens that offers vision at all distances—as do his patients. Dr. Berdahl is always looking for the latest technology in everything he does, which led him to the Alcon AcrySof IQ PanOptix Trifocal IOL. Now, he’s encouraging other surgeons to break free from their comfort zones and talk to patients about the benefits of choosing this lens.
I think that’s what makes life interesting and full—being able to pursue the sports, hobbies, and travel that you really enjoy. Modern-day patients want to feel that same freedom, and who can blame them?
PanOptix is the latest IOL that gives us the option to offer our patients vision at all distances: 20/20 near, 20/20 intermediate, and 20/20 distance is now possible.*,† ,1
Dr. John Berdahl on Breaking Free:
From scuba diving to surgery, the equipment John P. Berdahl, MD, uses is important to him, and he values equipment that offers him options. He believes the AcrySof IQ PanOptix Trifocal IOL is the latest technology to offer patients vision at all distances.
Vision is the most important of the senses because so much of our world comes to us through our sight. That is what, as ophthalmologists, we’re entrusted with. Our patients want to enjoy the same activities we do, and it’s our job to equip them with the latest technology to do so.
Break free from your comfort zone, limitations, the status quo, and tradition with the AcrySof IQ PanOptix Trifocal IOL.
In my practice, we pride ourselves on providing the right technology for the right patient, not simply fitting the patient to whatever technology we’re comfortable with. So it’s very telling that the PanOptix IOL very quickly became our go-to lens, based on both our experience and the evidence.
More surgeons on breaking free:
*Based on mean value of binocular defocus curve at near, intermediate and distance at 6 months (n=127).
†Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 ETDRS chart letters in the line were identified correctly.
1. AcrySof® IQ PanOptix® Directions for Use.
US-ACP-2000180
© 2020 Alcon Inc. 07/20
PanOptix is a trademark of Alcon. All other brand/product names are the trademarks of their respective owners.
AcrySof® IQ PanOptix® Family of Trifocal IOLs
IMPORTANT PRODUCT INFORMATION
CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.
INDICATIONS: The AcrySof® IQ PanOptix® Trifocal IOLs include AcrySof® IQ PanOptix® and AcrySof® IQ PanOptix® Toric and are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. In addition, the AcrySof® IQ PanOptix® Toric Trifocal IOL is indicated for the reduction of residual refractive astigmatism.
WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Physicians should target emmetropia and ensure that IOL centration is achieved.
For the AcrySof® IQ PanOptix® Toric Trifocal IOL, the lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction. If necessary, lens repositioning should occur as early as possible prior to lens encapsulation.
Some visual effects may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos or starbursts, as well as other visual symptoms. As with other multifocal IOLs, there is a possibility that visual symptoms may be significant enough that the patient will request explant of the multifocal IOL. A reduction in contrast sensitivity as compared to a monofocal IOL may be experienced by some patients and may be more prevalent in low lighting conditions. Therefore, patients implanted with multifocal IOLs should exercise caution when driving at night or in poor visibility conditions.
Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning).
As with other multifocal IOLs, patients may need glasses when reading small print or looking at small objects. Posterior capsule opacification (PCO) may significantly affect the vision of patients with multifocal IOLs sooner in its progression than patients with monofocal IOLs. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure, available from Alcon, informing them of possible risks and benefits associated with the AcrySof® IQ PanOptix® Trifocal IOLs.
ATTENTION: Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings and precautions.
